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Abstract 
Objective  To explore the safety and efficacy of FFR-guided percutaneous coronary intervention (PCI) in vessels with severe diameter 
stenosis. Methods & Results  Of 1090 patients undergoing fractional flow reserve (FFR) assessment from 2002 to 2009, we identified 167 
patients in whom FFR was measured in at least one 70%–89% stenotic lesion. These patients were subdivided into an FFR-defer group (n = 
49) if PCI was deferred (FFR > 0.80), and an FFR-perform group (n = 118) if PCI was performed (FFR  0.80). Comparatively, an addi-
tional 1176 patients undergoing PCI in at least one lesion with 70%–89% stenosis but without measurement of FFR served as a control (an-
giography-guided) group. Clinical outcomes were compared during a median follow-up of 49.0 months. The 5-year Kaplan-Meier estimated 
revascularization rates were 16% in the FFR-defer group and 33% in the FFR-perform group (P = 0.046). The incidence of major adverse 
cardiac events were comparable in these two groups (HR = 0.82, 95% CI: 0.37–1.82, P = 0.63). The number of stents placed was signifi-
cantly lower in the FFR-guided group (0.9 ± 0.8 vs. 1.4 ± 0.8, P < 0.001). Conclusions  Functional revascularization for lesions with visu-
ally severe stenosis is clinically safe and associated with fewer stents use. This study suggests that extending the use of FFR to more severe 
coronary lesions may be reasonable. 
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1  Introduction 
The benefits of percutaneous coronary intervention (PCI) 
are mainly attributable to the reduction of myocardial is-
chemia and symptoms,[1] and this is reflected in clinical 
practice guidelines which presently recommend PCI only 
when symptoms and/or myocardial ischemia are present.[2,3] 
Historically, most studies of coronary revascularization 
have been based on angiographic criteria, and have defined 
a “significant” stenosis as ≥ 70% diameter narrowing.[2] In 
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current interventional practice, visual assessment of the an-
giographic reduction of luminal diameter remains the stan-
dard measure to gauge the severity of lesions. However, 
evidence has shown that coronary angiography frequently 
fails to accurately identify the hemodynamic significance of 
lesions.[4,5] 
Fractional flow reserve (FFR), based on coronary pres-
sure measurements obtained during maximal hyperemia, 
has proven to be an accurate method to assess the functional 
significance of coronary stenosis.[6] In the last decade, the 
reliability of FFR has been established in various clinical 
and anatomical subsets.[7–17] In the FAME (Fractional Flow 
Reserve Versus Angiography for Multivessel Evaluation) 
and FAME 2 study, the decision-making to perform revas-
cularization based on FFR leads to favorable clinical out-
comes compared to conventional PCI or optimal medical 
therapy alone.[18,19] 
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Notably, more than half of the lesions in the FAME study 
were > 71% stenosis,[20] and 20% of them had FFR greater 
than 0.80.[21] Thus, the reliance on visual assessment has 
been questioned, and functional evaluation may be needed 
to identify the inducible ischemia for these angiographically 
severe lesions (> 70% diameter stenosis). Moreover, the 
baseline angiographic diameter stenosis has been reported to 
be associated with future myocardial infarction and major 
cardiac adverse events,[22] and incomplete revascularization 
may result in a higher event rate.[23] Therefore, the rationale 
for the use of FFR to evaluate severe stenosis is still uncer-
tain, and the safety of deferring PCI for a severe lesion 
based on FFR is unclear. 
The aim of this study is to preliminarily evaluate the 
usefulness of FFR-guided treatment strategy in patients with 
visually severe stenosis. We hypothesize that FFR-guide 
strategy is clinically reasonable. 
2  Methods 
2.1  Study population 
A total of 1090 consecutive patients with use of FFR at 
the Mayo Clinic in Rochester, Minnesota between October 
2002 and December 2009 were identified. Patients who 
underwent FFR measurement of at least one lesion with 
visual assessment of 70%–89% diameter stenosis were in-
cluded in the FFR-guided group. These patients were further 
divided into: (1) those without subsequent PCI (FFR-defer 
group), and (2) those in whom PCI were performed follow-
ing FFR measurement (FFR-perform group). Another, 6268 
consecutive patients who received PCI without prior FFR 
measurements in the same time period were screened, and  
only those undergoing PCI of at least one lesion with 70%– 
89% stenosis were included in the angiography- guided 
group (Figure 1). Because FFR was rarely used in lesions 
with 90%–99% stenosis, we did not include this subset of 
patients. 
Patients were excluded from study analysis if they met 
any of the following exclusion criteria: (1) presentation with 
myocardial infarction in the prior 24 h or cardiogenic shock; 
(2) referral for coronary artery bypass surgery; (3) presence 
of left main disease; (4) FFR measurement and/or PCI in at 
least one lesion with stenosis > 89%; (5) PCI of at least one 
vessel, with deferral of at least one other vessel after as-
sessment of FFR; (6) FFR ≤ 0.80 without PCI performed or 
PCI performance despite an FFR > 0.80; and (7) declined 
use of medical records for research purposes. 
Medical records of all patients were reviewed to obtain 
information on clinical, laboratory and angiographic char-
acteristics. The study was approved by the Institutional Re-
view Board of the Mayo Clinic. 
2.2  Intracoronary pressure measurements 
Intracoronary pressure measurement was performed us-
ing a 0.014-inch pressure-monitoring guidewire (Pressure 
Wire, Radi Medical, Uppsala, Sweden, or Wave Wire, Vol-
cano, Rancho Cordova, Calif). The pressure wire was in-
troduced via a 5F, 6F or 7F guiding catheter, calibrated and 
advanced into the coronary artery distal to the assessed 
stenosis as described previously.[6] Doses up to 72 μg of 
intracoronary adenosine were given to 1047 (96%) patients 
and intravenous adenosine at a rate of 140 μg/kg/min were 
administered to 43 (4%) patients for achievement of maxi- 
 
Figure 1.  Study-flow chart. FFR: fractional flow reserve; MACE: major adverse cardiac event; PCI: percutaneous coronary intervention. 
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mal coronary blood flow. Fractional flow reserve was cal-
culated as the ratio of the mean distal (trans stenotic) coro-
nary pressure measured by the pressure wire to mean aortic 
pressure measured by the guiding catheter at maximal hy-
peremia.[24] The threshold to perform or defer PCI was 
based on FFR of 0.80. 
2.3  Clinical follow-up 
Patients with PCI were followed via telephone calls at 6 
months, 12 months, and annually thereafter. Hospital re-
cords were reviewed to record follow-up events. Patients 
with deferred PCI were contacted via a single questionnaire 
and chart review. 
Clinical outcomes were compared between the FFR-per-
form and FFR-defer groups, and between the FFR-guided 
and angiography-guided groups. The primary endpoint was 
major adverse cardiac events (MACE), defined as compos-
ite of death, myocardial infarction (MI) or any revasculari-
zation. The secondary endpoints were the individual com-
ponents of MACE and the number of stents placed per pa-
tient. Death was all-cause mortality. MI was defined when 
two of the following three criteria were met: (1) prolonged 
chest pain > 20 minutes; (2) cardiac biomarker elevation > 2 
times normal limit; and (3) ST-T segment changes or new Q 
waves on serial electrocardiogram indicative of myocardial 
damage.[25] Revascularization was defined as any clinically 
driven revascularization including bypass surgery. 
2.4  Statistical analysis 
Continuous variables are summarized as mean ± SD for 
most variables, or median (25th, 75th percentile) where indi-
cated. Discrete variables are summarized as frequency (group 
percentage). Group comparisons are tested using Student’s 
two-sample t-test for most continuous variables, the rank 
sum test for FFR measurement comparisons, and Pearson’s 
chi-squared test for discrete data. Kaplan-Meier estimates 
were used to estimate survival curves, with the log-rank test 
employed to test differences between groups. Cox propor-
tional hazards multiple regression models were used to es-
timate the association between FFR use and deferral on 
long-term outcomes after adjusting for age, gender, body 
mass index, hypertension, high cholesterol, smoking status, 
diabetes, ejection fraction. These covariates were chosen 
based on clinical relevance. All significance tests were 
two-tailed with a 0.05 significance level. All analyses were 
conducted using SAS 9.2 (SAS Institute, Cary NC). 
3  Results 
3.1  Baseline characteristics 
In the FFR-guided group, 49 (29%) patients were deferred 
PCI (FFR-defer group) and 118 (71%) patients ultimately 
underwent PCI after FFR assessment (FFR-perform group). 
Patients in the former group were older and with lower 
prevalence of hypercholesterolemia. A total of 1176 patients 
were included in the angiography-guided group. The aver-
age number of stents placed was 0.9 ± 0.8 per patient in the 
FFR-guided and 1.4 ± 0.8 per patient in the angiogra-
phy-guided group (P < 0.001). More patients undergoing 
PCI received dual anti-platelet therapy on discharge. Clinical 
and angiographic characteristics of the each group are shown 
in Tables 1 & 2. In-hospital events are shown in Table 3. 
3.2  Follow-up 
Clinical events were collected during a median follow-up 
of 49.0 months (Q1, Q3: 23.0, 70.0). Length of follow-up 
was 39.8 (25.9, 72.6) months in the FFR-defer and 46.3 
(21.7, 65.3) months in the FFR-perform group (P = 0.68). 
The length of follow-up in the FFR-guided was 46.2 (24.0, 
65.9) months and 50.2 (22.9, 70.3) months in the angiogra-
phy-guided group (P = 0.08). The rate of follow-up was 
94% in the FFR-guided group and 97% the angiogra-
phy-guided group. 
3.3  Long-term outcomes between the FFR-defer and 
FFR-perform groups 
The 5-year Kaplan-Meier estimated event rates for MACE 
(28% vs. 41%, P = 0.18), mortality (13% vs. 10%, P = 0.44), 
MI (7% vs. 10%, P = 0.52), mortality or MI (20% vs. 19%, 
P = 0.73), and mortality or revascularization (28% vs. 40%, 
P = 0.22) were similar between the FFR-defer and FFR- 
perform groups, respectively (Figure 2). The revasculariza-
tion rate over 5 years was significantly lower in the FFR- 
defer group compared to the FFR-perform group (16% vs. 
33%, P = 0.046). 
After adjustment for age, sex, body mass index, inci-
dence of hypertension, hypercholesterolemia, smoking, 
diabetes, and left ventricular ejection fraction in a Cox mul-
tivariable model, the deferral of PCI based on FFR > 0.80 
did not increase the incidence of MACE (HR = 0.82, 
95% CI: 0.37–1.82, P = 0.63) or its component elements 
(Table 4). 
3.4  Long-term outcomes in the FFR-guided and angio-
graphy-guided groups 
The 5-year Kaplan-Meier event rates for MACE were 
37% and 38% (P = 0.83), mortality 11% and 18% (P = 
0.07), MI 9% and 8% (P > 0.99), mortality or MI 19% and 
24% (P = 0.18), revascularization 28% and 22% (P = 0.12), 
mortality or revascularization 36% and 37% (P = 0.78) in the 
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Table 1.  Baseline characteristics of patients. 
FFR-guided group (n = 167) 
Variables 
Angiography-guided group 
(n = 1176) All (n = 167) FFR-defer (n = 49) FFR-perform (n = 118) 
Age, yrs 67.0 ± 11.7 65.2 ± 11.5 68.0 ± 10.9ǂ  64.1 ± 11.7 
Male gender 746 (63.4%) 114 (68.3%) 29 (59.2%) 85 (72.0%) 
Body mass index 30.1 ± 6.2 30.9 ± 5.9 31.2 ± 6.2 30.7 ± 5.8 
Current smoking 117 (9.9%) 24 (14.4%) 4 (8.2%) 20 (17.0%) 
Diabetes mellitus 326 (27.7%) 49 (29.3%) 15 (30.6%) 34 (28.8%) 
Hypertension 902 (76.7%)§ 143 (85.6%) 43 (87.8%) 100 (84.7%) 
Hypercholesterolemia 918 (78.1%)* 116 (69.5%) 17 (35.0%)ƚ  99 (84.0%) 
Angina (CCS III~IV) 547 (46.5%) 80 (47.9%) 18 (36.7%) 62 (52.5%) 
History of MI (> 7 days) 265 (22.5%) 40 (24.0%) 11 (22.4%) 29 (24.6%) 
Prior PCI 349 (29.7%)* 74 (44.3%) 22 (44.9%) 52 (44.1%) 
History of CHF 143 (12.1%)§ 31 (18.6%) 10 (20.4%) 21 (17.8%) 
CVD 109 (9.3%) 13 (7.9%) 6 (12.2%) 7 (5.9%) 
PAD 117 (9.9%) 16 (9.6%) 5 (10.2%) 11 (9.3%) 
COPD 142 (12.1%) 13 (7.9%) 4 (8.2%) 9 (7.6%) 
Renal dysfunction 58 (4.9%) 5 (3.0%) 2 (4.1%) 3 (2.5%) 
LVEF ≤ 40% 100 (8.5%) 15 (9.0%) 5 (10.2%) 10 (8.5%) 
Aspirin on discharge 1135 (96.5%)§ 153 (91.6%) 43 (87.8%) 110 (93.2%) 
Clopidogrel on discharge 1151 (97.9%)* 128 (76.6%) 13 (26.5%)ƚ  115 (97.5%) 
Beta-blockers on discharge 903 (76.8%) 130 (77.8%) 37 (75.5%) 93 (78.8%) 
Calcium channel blocker on discharge 208 (17.7%) 35 (21.0%) 8 (16.3%) 27 (22.9%) 
ACE inhibitors on discharge 677 (57.6%) 92 (55.1%) 22 (44.9%) 70 (59.3%) 
Lipid lowering drugs on discharge 592 (50.3%)* 102 (61.1%) 38 (77.6%)ǂ  64 (54.2%) 
Data are presented as means ± SD or n (%). §P < 0.05 as compared to FFR-guided group; *P < 0.001 as compared to FFR-guided group; ǂ P < 0.05 as compared 
to FFR-perform group; ƚ P < 0.001 as compared to FFR-perform group. CCS: Canadian Cardiovascular Society; CHF: chronic heart failure; COPD: chronic 
obstructive pulmonary disease; CVD: cerebral vascular disease; FFR: fractional flow reserve; LVEF: left ventricular ejection fraction; MI: myocardial infarc-
tion; PAD: peripheral artery disease; PCI: percutaneous coronary intervention. 
Table 2.  Angiography and PCI characteristics. 
FFR-guided group (n = 167) 
Variables 
Angiography-guided 
group (n = 1176)  All (n = 167) FFR-defer (n = 49) FFR-perform (n = 118) 
LAD stenosis ≥ 70% 697 (59.3%)§ 113 (67.7%) 25 (51.0%)ǂ  88 (74.6%) 
LCX stenosis ≥ 70% 329 (30.0%) 38 (22.6%) 15 (30.6%)ǂ  23 (19.5%) 
RCA stenosis ≥ 70% 423 (36.0%) 41 (24.6%) 13 (26.5%) 28 (23.7%) 
FFR in LAD -- 118 (70.7%) 32 (65.3%) 86 (72.9%) 
FFR in LCX -- 22 (13.2%) 9 (18.4%) 13 (11.0%) 
FFR in RCA -- 30 (18.1%) 10 (20.4%) 20 (16.9%) 
Median FFR value (Q1, Q3) -- 0.77 (0.70, 0.82) 0.88 (0.83, 0.91)ƚ  0.74 (0.68, 0.77) 
PCI in native LAD 660 (56.1%) 88 (50.9%) -- 88 (74.6%) 
PCI in native LCX 284 (24.1%)* 17 (10.2%) -- 17 (14.4%) 
PCI in native RCA 396 (33.7%)* 22 (13.4%) -- 26 (22.0%) 
Number of vessel treated 
1 1023 (87.0%) 105 (63.0%) -- 105 (89.0%) 
2 146 (12.4%) 13 (7.8%) -- 13 (11.0%) 
3 4 (0.3%) 0 -- 0 
Number of stents placed 1.4 ± 0.8* 0.9 ± 0.8 -- 1.3 ± 0.7 
Procedural success of stents placement 1161 (98.7%) -- -- 117 (99.2%) 
Data are presented as means ± SD or n (%). §P < 0.05 as compared to FFR-guided group; *P < 0.001 as compared to FFR-guided group; ǂ P < 0.05 as compared 
to FFR-perform group; ƚ P < 0.001 as compared to FFR-perform group. FFR: fractional flow reserve; LAD: left anterior descending; LCX: left circumflex; PCI: 
percutaneous coronary intervention; RCA: right coronary artery. 
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Table 3.  In-hospital events. 
FFR-guided group (n = 167)  
Variables 
Angiography-guided group  
(n = 1176) All 
(n = 167) 
FFR-defer 
(n = 49) 
   FFR-perform 
   (n = 118) 
 
 
Death 0 0 0 0 
Death/Q-wave MI/stroke/CABG 2 (0.2%) 0 0 0 
Q-wave MI 0 0 0 0 
Emergency CABG 0 0 0 0 
In-hospital CVD 2 (0.2%) 0 0 0 
In-hospital any MI 41 (3.5%) 6 (3.4%) 0 6 (5.1%) 
Data are presented as n (%). CABG: coronary artery bypass grafting; CVD: cerebral vascular disease; FFR: fractional flow reserve; MI: myocardial infarction. 
 
Figure 2.  Long-term adverse events in FFR-defer group vs.FFR-perform group. (A): Kaplan-Meier curves for MACE during fol-
low-up; (B): Kaplan-Meier curves for death during follow-up; (C): Kaplan-Meier curves for myocardial infarction during follow-up; and (D): 
Kaplan-Meier curves for revascularization during follow-up. FFR: fractional flow reserve; MACE: major adverse cardiac events; PCI: per-
cutaneous coronary intervention. 
FFR-guided group and the angiography-guided group, respec-
tively (Figure 3). In the Cox multivariable model, no diffe-
rences in the risk of outcome events between groups (Table 4). 
4  Discussion 
In this study, when FFR was used to assess the functional 
significance in lesions with 70%–89% stenosis, PCI was de-
ferred in almost one third of patients. Importantly, their in-
cidence of MACE was lower compared to those undergoing 
PCI although this was only statistically significant for the 
endpoint of repeat revascularization, indicating that deferral 
of PCI based on FFR > 0.80 is clinically safe. Compared 
to conventional PCI, the FFR-guided treatment strategy 
was associated with a significantly lower number of stents 
placed. 
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Figure 3.  Long-term adverse events in FFR-defer group vs. angiography-guided group. (A): Kaplan-Meier curves for MACE during 
follow-up; (B): Kaplan-Meier curves for death during follow-up; (C): Kaplan-Meier curves for myocardial infarction during follow-up; and 
(D): Kaplan-Meier curves for revascularization during follow-up. FFR: fractional flow reserve; MACE: major adverse cardiac events; PCI: 
percutaneous coronary intervention. 
Table 4.  Cox multivariable models to identify hazard ratio of outcome events. 
Events Adjusted* HR 95% CI P-value 
Deferred PCI after FFR vs. Perform PCI 
MACE 0.82 0.37–1.82 0.63 
Revascularization 0.51 0.18–1.45 0.20 
Mortality or Revascularization 0.85 0.38–1.91 0.70 
Mortality or Myocardial infarction 1.60 0.53–4.89 0.41 
FFR use vs. no FFR 
MACE 1.06 0.79–1.43 0.69 
Mortality 0.67 0.39–1.14 0.14 
Mortality or Revascularization 1.07 0.79–1.43 0.70 
Mortality or Myocardial infarction 0.83 0.54–1.27 0.39 
*Adjusted for age, sex, body mass index, smoking history, diabetes, hypertension, hypercholesterolemia, left ventricular ejection fraction. FFR: fractional flow 
reserve; MACE: major adverse cardiac events; PCI: percutaneous coronary intervention. 
 
Although the FAME study suggests that angiography is 
inaccurate in assessing functional significance for both in-
termediate and severe stenoses, no further investigation has 
been conducted to explore the rationale for the use of FFR 
in lesions of ≥ 70% stenosis.[21] Moreover, the role of di-
ameter narrowing severity in predicting future events has 
been demonstrated in previous studies.[22,26] When using the 
residual SYNTAX score based on angiographic appearance 
to quantify and risk-stratify the degree and complexity of 
residual stenosis after PCI, incomplete revascularization is 
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associated with a worse prognosis compared with complete 
revascularization.[23] Hannan, et al.[27] reported that incom-
plete revascularization was associated with suboptimal 
long-term outcome. Therefore, the safety of deferring PCI in 
a functionally non-significant, but angiographically severe 
lesion is still a potential concern. However, the COURAGE 
trial (Clinical Outcomes Utilizing Revascularization and 
Aggressive Drug Evaluation) has reported no difference in 
outcomes between PCI plus optimal medical therapy and 
optimal medical therapy alone in patients with over 70% 
stenosis.[28] As is known, angiography only depicts coronary 
anatomy from a planar two-dimensional silhouette of the 
lumen, and provides little characterization of plaque mor-
phology or vessel wall, both of which play an important role 
in plaque destabilization.[29] In the recent PROSPECT trial 
(Providing Regional Observations to Study Predictors of 
Events in the Coronary Tree), a small luminal area and large 
plaque burden measured by intravascular ultrasound were 
significant predictors of subsequent events, but there was no 
relationship between stenotic severity on conventional an-
giography and prognosis.[30] The current study, to our 
knowledge, firstly demonstrated that deferral of PCI based 
on FFR resulted in similar, if not improved, long-term out-
comes compared to performing PCI, underscoring the safety 
of an FFR-guided approach. 
The incidence of 5-year repeat revascularization was 
16% in the FFR-defer group, which was significantly lower 
than that in the FFR-perform group (33%). A similar con-
clusion has been reported in the FAME study,[20] where only 
one third of repeat revascularizations during follow-up were 
related to the originally deferred lesions. In the DEFER 
study (Fractional Flow Reserve to Determine the Appropri-
ateness of Angioplasty in Moderate Coronary Stenosis ), 
even when treated by PCI, the chance of adverse events 
related to a functionally significant stenosis in the next 5 
years was several times higher than for a stenosis of similar 
angiographic severity but not associated with reversible 
ischemia and treated medically.[12] Importantly, in the cur-
rent study, the difference in the rates of repeat revasculari-
zation between the FFR-defer and FFR-perform groups 
appeared after 13 months of the index procedure, and be-
came more significant over time, which indicating that this 
benefit mainly derives from fewer late or very late adverse 
events, and not from reduction of periprocedural complica-
tions. 
Of those lesions considered angiographically severe, the 
vast majority are hemodynamically significant, therefore 
routine use of FFR will likely be controversial given the 
associated costs.[31] In this study, the FFR-guided group was 
associated with fewer stents placed. Considering that the 
pressure wire is applicable for PCI after measurement of 
FFR, in addition to lower amount of contrast media and dual 
anti-platelet therapy, functional revascularization should be 
more economic. Furthermore, Fearon, et al.[32] reported that 
30% of the overall cost benefits of FFR-guided treatment 
strategy was generated during follow-up. In our study, fewer 
repeat revascularizations in the next five years may lead to 
further cost savings after the initial procedure. 
In the current study, the difference in outcomes between 
the FFR-guided and angiography-guided groups was not as 
significant as shown in the FAME study.[20] This may 
mainly be attributable to the relatively higher proportion of 
functionally severe lesions in this stenosis subset compared 
to the intermediate stenosis. 
4.1  Limitation 
This is a single-center, observational study. Small sample 
size and its retrospective design limit the statistical power 
and strength of the conclusions. It was performed in a 
non-selected population of everyday practice with differ-
ences in baseline characteristics. Multiple regression analy-
sis may mitigate bias after adjustment of confounding fac-
tors, but unmeasured indicators of FFR use leave room for 
residual bias. 
PCI patients are followed regularly by telephone as stan-
dard clinical practice, but FFR patients who did not have 
any PCI performed had their follow-up information col-
lected via a questionnaire and history review. Events outside 
our institution may have been missed in FFR patients who 
did not return their questionnaire. On the other hand, 
healthy patients with no events who did not return to Mayo 
may have been excluded for lack of follow-up. 
96% of the patients received escalating doses of adeno-
sine up to 72 μg in this study until maximal hyperemia and 
the lowest FFR were achieved. Nevertheless, some studies 
reported that an intracoronary bolus dose > 300 μg could be 
equal to or more effective in achieving maximum hypere-
mia when calculating the FFR. Therefore, the dose of intra-
coronary adenosine used in this study might be too low, 
resulting in misclassification for some patients. 
4.2  Conclusion 
The FFR-guided strategy is safe to include in the deci-
sion making process for PCI in patients with severe stenosis. 
This study extends the validation of functional assess-
ment-based revascularization to more severe coronary le-
sions. Randomized, controlled studies with large sample 
size are needed to confirm our preliminary findings. 
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